Theophylline


Curated chemical-phenotype interactions from CTD
GO IDGO nameInteraction typeReference
GO:0000278 Mitotic cell cycle Decreases phenotype PMID:4334033; PMID:6449284
GO:0002027 Regulation of heart rate Increases phenotype PMID:1874263; PMID:3956056; PMID:6313028; PMID:6510459; PMID:8237803; PMID:2438095; PMID:3425350; PMID:7743391; PMID:8382824
GO:0005980 Glycogen catabolic process Increases phenotype PMID:14577594; PMID:3018195
GO:0006198 Camp catabolic process Affects phenotype PMID:26851681
GO:0006309 Apoptotic dna fragmentation Increases phenotype PMID:14634331
GO:0006749 Glutathione metabolic process Affects phenotype PMID:26851681
GO:0006874 Cellular calcium ion homeostasis Affects phenotype PMID:27262380
GO:0006915 Apoptotic process Increases phenotype PMID:10770286; PMID:10891529; PMID:11095404; PMID:11128117; PMID:14634331; PMID:15313391; PMID:15313391; PMID:15645133; PMID:15370247; PMID:8822937; PMID:15645133; PMID:18534089; PMID:8556412; PMID:8822937; PMID:9312165; PMID:9344607; PMID:9344607; PMID:9454737; PMID:9454737
GO:0006979 Response to oxidative stress Increases phenotype PMID:12927907
GO:0008217 Regulation of blood pressure Increases phenotype PMID:6510459
GO:0008219 Cell death Increases phenotype PMID:15313391
GO:0008283 Cell population proliferation Affects phenotype PMID:11694023; PMID:17459420; PMID:7271315
GO:0016042 Lipid catabolic process Increases phenotype PMID:1019147; PMID:184721; PMID:7155675; PMID:8245724; PMID:11160373; PMID:4306506; PMID:1193734; PMID:1659919; PMID:184721; PMID:2930584; PMID:2930584; PMID:6249948; PMID:3308432; PMID:4306506; PMID:7155675; PMID:8302948
GO:0019222 Regulation of metabolic process Affects phenotype PMID:31568846
GO:0019233 Sensory perception of pain Increases phenotype PMID:16636964
GO:0030316 Osteoclast differentiation Increases phenotype PMID:26851681
GO:0030501 Positive regulation of bone mineralization Decreases phenotype PMID:26851681
GO:0030595 Leukocyte chemotaxis Affects phenotype PMID:10947063; PMID:11408767; PMID:10947063; PMID:1659436; PMID:12016098; PMID:1659436
GO:0032229 Negative regulation of synaptic transmission, gabaergic Increases phenotype PMID:1678016
GO:0034440 Lipid oxidation Increases phenotype PMID:26851681
GO:0042119 Neutrophil activation Increases phenotype PMID:9762784
GO:0042310 Vasoconstriction Increases phenotype PMID:3142892; PMID:3559983; PMID:537246; PMID:8626879; PMID:9362105
GO:0042311 Vasodilation Increases phenotype PMID:15001965; PMID:2225701; PMID:2283195; PMID:8436613; PMID:8626879
GO:0042438 Melanin biosynthetic process Increases phenotype PMID:32001318
GO:0043065 Positive regulation of apoptotic process Increases phenotype PMID:26851681
GO:0045780 Positive regulation of bone resorption Increases phenotype PMID:26851681
GO:0045930 Negative regulation of mitotic cell cycle Increases phenotype PMID:26851681
GO:0046466 Membrane lipid catabolic process Affects phenotype PMID:10921764; PMID:12927907; PMID:15792369
GO:0046649 Lymphocyte activation Decreases phenotype PMID:8730004
GO:0051452 Intracellular ph reduction Increases phenotype PMID:9454737
GO:0051881 Regulation of mitochondrial membrane potential Decreases phenotype PMID:18534089
GO:0051967 Negative regulation of synaptic transmission, glutamatergic Increases phenotype PMID:1678016
GO:0055062 Phosphate ion homeostasis Decreases phenotype PMID:26851681
GO:0055074 Calcium ion homeostasis Decreases phenotype PMID:26851681
GO:0060048 Cardiac muscle contraction Increases phenotype PMID:6510459
GO:0070640 Vitamin d3 metabolic process Affects phenotype PMID:26851681
GO:0097280 Histamine secretion mediated by immunoglobulin Affects phenotype PMID:1707400; PMID:2417477; PMID:2431021; PMID:2441100; PMID:6182749; PMID:2448357; PMID:6182749; PMID:70945; PMID:8689388
GO:1903428 Positive regulation of reactive oxygen species biosynthetic process Increases phenotype PMID:26851681
GO:1904457 Positive regulation of neuronal action potential Increases phenotype PMID:29596924
GO:1990523 Bone regeneration Decreases phenotype PMID:26851681
GO:2001171 Positive regulation of atp biosynthetic process Decreases phenotype PMID:26921665
DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.